Barrett J. Rollins, MD, PhD, Faculty Chair
Chief Scientific Officer
Linde Family Professor of Medicine,
Harvard Medical School

Barrett J. Rollins, MD, PhD, is charged with fostering collaboration among investigators and helping them obtain the resources they need to keep Dana-Farber at the forefront of cancer research.

Dr. Rollins’ own research investigates the effects of inflammation on the development and progression of cancer. His laboratory helped identify the molecular signals that direct the movement and activation of white blood cells during inflammatory responses. Dr. Rollins’ group discovered that some of these same signals stimulate cancer growth, suggesting that they could be targets for novel cancer treatments. Most recently, his laboratory described the first genetic abnormality in a rare childhood disease called Langerhans cell histiocytosis, and his group is using this discovery to develop new treatments for this disease.

A graduate of Amherst College, Dr. Rollins earned his Doctor of Medicine and Doctor of Philosophy at Case Western Reserve University. He completed his internship and residency in internal medicine at Beth Israel Hospital, Boston. Dr. Rollins came to Dana-Farber in 1983 as a clinical fellow in medical oncology, and was named Dana-Farber’s first Chief Scientific Officer in 2004. He is a member of the American Society for Clinical Investigation and the Association of American Physicians, and is a Fellow of the American Association for the Advancement of Science.
Ed Chouchani, PhD
Assistant Professor, Cell Biology

Edward Chouchani, PhD, received his Doctor of Philosophy in Biological Sciences at the University of Cambridge in the United Kingdom. After completing postdoctoral research at Harvard Medical School, he joined Harvard Medical School and Dana-Farber Cancer Institute as an Assistant Professor of Cell Biology in 2017. Dr. Chouchani’s lab applies mass spectrometry and biochemical approaches to identify mechanisms that control disease progression in metabolic diseases and diseases of aging.

Most recently, Dr. Chouchani’s work uncovered new metabolic singling mechanisms that control the anti-obesity calorie burning function of thermogenic adipose tissue. His work has identified new pathways that could be leveraged to treat human metabolic disease. Dr. Chouchani has been recognized by numerous international awards, including The Biochemical Society Young Investigator Award, The British Society for Cardiovascular Research Young Investigator Award, and an August Krogh Rising Star in Physiology.
Jeffrey Meyerhardt, MD, MPH, FASCO
Senior Physician/Clinical Director,
Gastrointestinal Cancer Center
Deputy Clinical Research Officer
Douglas Gray Woodruff Chair in Colorectal Cancer
Research at Dana-Farber
Professor of Medicine, Harvard Medical School

Jeffrey Meyerhardt, MD, MPH, FASCO, earned his medical degree from Yale University School of Medicine in New Haven, Conn. and completed an internship and residency in medicine at Beth Israel Deaconess Medical Center in Boston, Mass. He completed a clinical fellowship in medical oncology at Dana-Farber Cancer Institute and Massachusetts General Hospital. Dr. Meyerhardt also holds a Master of Public Health from Harvard T.H. Chan School of Public Health in Boston.

Dr. Meyerhardt has two main areas of research focus – studying host factors and energy balance in colorectal cancer patients and involvement in clinical trials for gastrointestinal cancer, serving as the co-chair of the Gastrointestinal Cancer Committee for the Alliance for Clinical Trials in Oncology.
Lesley Solomon became Dana-Farber’s Senior Vice President and Chief Innovation Officer in 2017. She has previously served as the founding executive director of Brigham and Women’s Hospital’s Innovation Hub, and as director of strategy and innovation in the Brigham Research Institute.

Ms. Solomon has more than 20 years of experience as an executive working in business development, strategy, and marketing at startups, early-stage, and large companies such as the Food Network, Barnes & Noble.com, and Yoga Works. She received her Master of Business Administration from Harvard Business School and has a Bachelor of Arts in English from Cornell University. She is a co-founder of the Food Allergy Science Initiative at The Broad Institute of MIT and Harvard, which brings together experts across disciplines to unlock the biology of food allergy and change the field to develop new treatments and more.
Bruce M. Spiegelman, PhD
Stanley J. Korsmeyer Professor, Harvard Medical School

Bruce M. Spiegelman, PhD, received a Bachelor of Science with highest honors from the College of William and Mary in 1974, his Doctor of Philosophy in biochemistry from Princeton University in 1978 and completed postdoctoral work at Massachusetts Institute of Technology. He joined Harvard Medical School and Dana-Farber Cancer Institute in 1982. His research focuses on fat cell biology, diabetes and muscular diseases.

Major honors include Bristol-Myers Squibb Award for Distinguished Achievement in Metabolic Research; Rolf Luft Award in Endocrinology, Karolinska Institute; the Banting Medal for Scientific Achievement, American Diabetes Association; Manpei Suzuki International Prize for Diabetes Research (Japan), InBev-Baillet Latour Health Prize, Belgium. Dr. Spiegelman has been elected to the American Academy of Arts and Sciences, the National Academy of Sciences and the Institute of Medicine of the National Academies.